LADENBURG THALM/SH SH downgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from a buy rating to a neutral rating in a research report sent to investors on Friday morning, Benzinga reports.
Other analysts have also recently issued reports about the stock. Guggenheim dropped their target price on shares of SAGE Therapeutics from $200.00 to $110.00 and set a buy rating on the stock in a report on Thursday. Royal Bank of Canada decreased their price target on shares of SAGE Therapeutics from $190.00 to $100.00 and set an outperform rating for the company in a report on Friday. Wedbush lowered their price objective on shares of SAGE Therapeutics from $203.00 to $90.00 and set an outperform rating for the company in a research report on Thursday. Goldman Sachs Group dropped their price objective on shares of SAGE Therapeutics from $227.00 to $263.00 in a research note on Thursday. Finally, HC Wainwright cut their target price on shares of SAGE Therapeutics from $160.00 to $87.00 and set a neutral rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. SAGE Therapeutics presently has a consensus rating of Buy and a consensus target price of $128.81.
SAGE stock opened at $64.46 on Friday. The company has a current ratio of 12.67, a quick ratio of 12.67 and a debt-to-equity ratio of 0.03. The firm has a market cap of $3.34 billion, a P/E ratio of -7.98 and a beta of 2.52. SAGE Therapeutics has a 12-month low of $56.50 and a 12-month high of $193.56. The stock’s 50 day simple moving average is $142.30 and its 200 day simple moving average is $160.81.
Hedge funds and other institutional investors have recently modified their holdings of the company. Wealthcare Advisory Partners LLC grew its holdings in SAGE Therapeutics by 150.0% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 250 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 150 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in SAGE Therapeutics during the 2nd quarter valued at $44,000. Tobam bought a new stake in SAGE Therapeutics during the 2nd quarter valued at $92,000. Tower Research Capital LLC TRC acquired a new position in SAGE Therapeutics during the 2nd quarter worth $111,000. Finally, Athanor Capital LP acquired a new position in SAGE Therapeutics during the 2nd quarter worth $201,000.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
Further Reading: What are catch-up contributions?
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.